Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (30)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by André, T.
Right arrow Articles by Izrael, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by André, T.
Right arrow Articles by Izrael, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 7:173-178, 1996
© 1996 European Society for Medical Oncology

research-article

Phase II trial of 5-fluorouracil, leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma

T. André1, J. P. Lotz1, C. Bouleuc1, K. Azzouzi1, S. Houry3, L. Hannoun4, J. See2, A. Esteso1, D. Avenin1 and V. Izrael1

1Departments of Medical Oncology, Saint-Antoine Hospital Paris, France
2Departments ofGastroenterology, Saint-Antoine Hospital Paris, France
3Departments of Surgery, Tenon Hospital Paris, France
4Department of Surgery, Saint-Antoine Hospital Paris, France

Thierry André, M.D. Service d'Oncologie Medicale Professeur V. Izrael Hopital Tenon 4, rue de la Chine 75020 Paris, France

Background. Advanced pancreatic adenocarcinoma is a rapidly fatal disease for which an active chemotherapy regimen is sought. Here we report the outcome of a phase II trial to assess the toxicity and efficacy of a combination of 5-flu-orouracil (5-FU), leucovorin and cisplatin (CDDP).

Methods. A regimen combining leucovorin (200 mg/m2/d x 5d), 5-FU (375 mg/m2/d x 5d in a 2-hour infusion) and CDDP (15 mg/m2/d x 5d) was given to 52 patients with histologically-proven, previously untreated, locally advanced (n = 13) and/or metastatic (n = 39) pancreatic adenocarcinoma.

Results. Of 48 patients evaluable for response, 10 achieved partial responses, for an overall response rate of 21% (95% CI 9.5%–32.5%), and a palliative effect was observed in 52%. The median survival was 9.5 months (18 months for locally-advanced and 5 months for metastatic disease) with a 1-year survival of 34.6% and a median progression-free survival of 4.5 months. Chemotherapy was well tolerated with grades 3 or 4 nausea/vomiting in 12%, diarrhea in 6%, anaemia in 17%, neutropenia in 12%, and thrombocytopenia in 10%. Eleven patients (21%) had Grade 2 peripheral neuropathy.

Conclusion. The combination of leucovorin, 5-FU and CDDP seems to be an effective palliative treatment, with moderate toxic effects, in advanced pancreatic adenocarcinoma.

advanced pancreatic adenocarcinoma, cisplatin, 5-fluorouracil, leucovorin


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
N. Xiros, P. Papacostas, T. Economopoulos, G. Samelis, E. Efstathiou, E. Kastritis, H. Kalofonos, A. Onyenadum, D. Skarlos, A. Bamias, et al.
Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group
Ann. Onc., May 1, 2005; 16(5): 773 - 779.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
F. G. El Kamar, M. L. Grossbard, and P. S. Kozuch
Metastatic Pancreatic Cancer: Emerging Strategies in Chemotherapy and Palliative Care
Oncologist, February 1, 2003; 8(1): 18 - 34.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Ducreux, P. Rougier, J.-P. Pignon, J.-Y. Douillard, J.-F. Seitz, R. Bugat, J.-F. Bosset, Y. Merouche, J.-L. Raoul, M. Ychou, et al.
A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma
Ann. Onc., August 1, 2002; 13(8): 1185 - 1191.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
M Voss, P Hammel, G Molas, L Palazzo, A Dancour, D O'Toole, B Terris, C Degott, P Bernades, and P Ruszniewski
Value of endoscopic ultrasound guided fine needle aspiration biopsy in the diagnosis of solid pancreatic masses
Gut, February 1, 2000; 46(2): 244 - 249.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.